In the Zone

$PCYC - Pharmacyclics, Inc.

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on discovering, developing, and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.

Its products in clinical development includes PCI-32765, an orally active small molecule inhibitor of Bruton’s tyrosine kinase (Btk), which is in phase II studies for the treatment of patients with B-cell lymphoma or leukemia; PCI-27483, an inhibitor of Factor VIIa, which is in phase II clinical trial for the treatment of pancreatic cancer; PCI-24781, a histone deacetylase (HDAC) inhibitor in phase I and II clinical trials in solid tumors and hematological malignancies; HDAC8 Isoform-specific Inhibitor for T-cell leukemia and lymphoma, neuroblastoma, and autoimmune disease.

The company’s pre-clinical programs include Btk inhibitor program for autoimmune disease; and HDAC8 inhibitor program for cancer. The company has a license agreement with the University of Texas to develop and commercialize porphyrins; expanded porphyrins, such as motexafin gadolinium; and other porphyrin-like substances.

It also has a collaboration and license agreement with Servier. The company was founded in 1991 and is headquartered in Sunnyvale, California.

Please keep $PCYC - Pharmacyclics, Inc. on your radar for a price move above $17.96 - $18.02 on heavier than average average daily trading volume of 753,430.

As the week came to a close (PCYC) Pharmacylics, Inc. ended trading at $16.64 up $0.09 or +0.54% on lighetr than average weekly upside volume of 1.91 million. The average weekly trading volume for (PCYC) Pharmacyclics, Inc. is 3.62 million.

This is not a buy recommendation please do your own due diligence or get help from a professional before trading.

By: Marlin Rolle

*** Please have a close look at the charts listed below ****